JaLCDOI 10.18926/AMO/59951
FullText URL 74_3_209.pdf
Author Matsui, Yusuke| Hiraki, Takao| Iguchi, Toshihiro| Sakurai, Jun| Uka, Mayu| Masaoka, Yoshihisa| Gobara, Hideo| Kanazawa, Susumu|
Abstract An aspiration-type semi-automatic cutting biopsy needle enables tissue cutting during application of negative pressure, which is expected to contribute to a larger amount of specimen. The aim of the present study was to evaluate this novel needle in a clinical setting. Patients who underwent image-guided percutaneous biopsy for lung or renal masses were enrolled. Cutting biopsy was performed with and without aspiration during each procedure. The specimens were weighed using an electronic scale. The weights were compared between specimens obtained with and without aspiration using a paired t-test. The data from 45 lung and 30 renal biopsy procedures were analyzed. In lung biopsy, the mean±standard deviation weights of specimens obtained with and without aspiration were 2.20±1.05 mg and 2.24±1.08 mg, respectively. In renal biopsy, the mean weights were 6.52±2.18 mg and 6.42±1.62 mg, respectively. The weights were not significantly different between specimens obtained with and without aspiration either in lung (p=0.799) or renal (p=0.789) biopsies. The application of negative pressure with the aspiration-type semi-automatic cutting biopsy needle did not contribute to an increase in the amount of the specimen obtained in lung and renal biopsies.
Keywords biopsy cutting needle aspiration clinical study
Amo Type Original Article
Published Date 2020-06
Publication Title Acta Medica Okayama
Volume volume74
Issue issue3
Publisher Okayama University Medical School
Start Page 209
End Page 214
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 32577018
Author Tanaka, Takashi| Huang, Yong| Marukawa, Yohei| Tsuboi, Yuka| Masaoka, Yoshihisa| Kojima, Katsuhide| Iguchi, Toshihiro| Hiraki, Takao| Gobara, Hideo| Yanai, Hiroyuki| Nasu, Yasutomo| Kanazawa, Susumu|
Keywords MDCT artificial intelligence kidney neoplasms neural network models
Published Date 2020-01-08
Publication Title American journal of roentgenology
Publisher American Roentgen Ray Society
Start Page 1
End Page 8
ISSN 0361-803X
NCID AA00521224
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 31913072
DOI 10.2214/AJR.19.22074
Related Url isVersionOf https://doi.org/10.2214/AJR.19.22074
JaLCDOI 10.18926/AMO/56871
FullText URL 73_3_269.pdf
Author Tsuboi, Ichiro| Araki, Motoo| Fujiwara, Hiroyasu| Iguchi, Toshihiro| Hiraki, Takao| Arichi, Naoko| Kawamura, Kasumi| Maruyama, Yuki| Mitsui, Yosuke| Sadahira, Takuya| Kubota, Risa| Nishimura, Shingo| Sako, Tomoko| Takamoto, Atsushi| Wada, Koichiro| Kobayashi, Yasuyuki| Watanabe, Toyohiko| Yanai, Hiroyuki| Kitagawa, Masashi| Tanabe, Katsuyuki| Sugiyama, Hitoshi| Wada, Jun| Shiina, Hiroaki| Kanazawa, Susumu| Nasu, Yasutomo|
Abstract Nephron-sparing treatment should be offered whenever possible to avoid dialysis in allograph cases. Cryoablation is a new treatment option for treating small-sized renal cell cancer (RCCs). We report a case of RCC arising in a kidney allograft treated by cryoablation. To our knowledge, this is the first case in Asia of RCC in a renal allograft treated using cryoablation. Contrast-enhanced CT-guided percutaneous renal needle biopsy and cryoablation were used to identify the RCC, which could not be identified by other techniques. The postoperative course was uneventful. Contrast-enhanced CT also showed no recurrence or metastases at the 6-month follow-up.
Keywords cryoablation partial nephrectomy renal cell carcinoma renal allograft renal transplantation
Amo Type Case Report
Published Date 2019-06
Publication Title Acta Medica Okayama
Volume volume73
Issue issue3
Publisher Okayama University Medical School
Start Page 269
End Page 272
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31235976
JaLCDOI 10.18926/AMO/54817
FullText URL 70_6_511.pdf
Author Gobara, Hideo| Hiraki, Takao| Iguchi, Toshihiro| Fujiwara, Hiroyasu| Nagasaka, Takeshi| Kishimoto, Hiroyuki| Tanaka, Takehiro| Kanazawa, Susumu|
Abstract An 87-year-old Japanese man underwent percutaneous cryoablation (PCA) therapy for his renal cell tumor. We displaced the colon from the tumor using hydrodissection. Computed tomography (CT) immediately after PCA was indicative of iceball extension to the colon wall, and a discontinuous enhancement of the colon wall was observed. We therefore performed an emergency surgery. On laparotomy, we observed a dark-purple area on the affected area of the colon, and the resected specimen showed focal, deep ulceration on the mucosal surface. Photomicrography revealed mucosal necrosis, submucosal hemorrhage, and necrotic foci in the muscularis propria, corresponding to the discontinuous colon wall enhancement on CT and the deep ulceration and dark-purple area on laparotomy. He recovered from surgery and was discharged without any complications.
Keywords bowel injury complication cryoablation renal cell carcinoma thermal ablation
Amo Type Case Report
Published Date 2016-12
Publication Title Acta Medica Okayama
Volume volume70
Issue issue6
Publisher Okayama University Medical School
Start Page 511
End Page 514
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28003679
JaLCDOI 10.18926/AMO/54512
FullText URL 70_4_317.pdf
Author Sakurai, Jun| Matsui, Yusuke| Hiraki, Takao| Iguchi, Toshihiro| Fujiwara, Hiroyasu| Gobara, Hideo| Mitsuhashi, Toshiharu| Nagasaka, Takeshi| Susumu Kanazawa, Susumu Kanazawa|
Abstract The present single center prospective phase II clinical trial is designed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases. Patients who have colorectal lung metastases without extrapulmonary metastases are included in this study. The primary endpoint is 3-year overall survival (OS) after RF ablation. The secondary endpoints are the prevalence of adverse events within 4 weeks, local tumor progression rate, 1- and 5-year OS, cause-specific survival, and relapse-free survival. The recruitment of patients commenced in July 2014, and the enrolment of 45 patients is intended over the 3 years of study period.
Keywords radiofrequency ablation colorectal cancer lung metastasis
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 317
End Page 321
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549681
Web of Science KeyUT 000384748600016
JaLCDOI 10.18926/AMO/54509
FullText URL 70_4_303.pdf
Author Iguchi, Toshihiro| Sakurai, Jun| Hiraki, Takao| Gobara, Hideo| Fujiwara, Hiroyasu| Matsui, Yusuke| Masaoka, Yoshihisa| Kanazawa, Susumu|
Abstract This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.
Keywords cryoablation soft tissue and bone tumor pain safety
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 303
End Page 306
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549678
Web of Science KeyUT 000384748600013
JaLCDOI 10.18926/AMO/54505
FullText URL 70_4_285.pdf
Author Tanaka, Takashi| Gobara, Hideo| Inai, Ryota| Iguchi, Toshihiro| Tada, Akihiro| Sato, Shuhei| Yanai, Hiroyuki| Kanazawa, Susumu|
Abstract We present a case of a 66-year-old man with esophageal carcinoma. 18Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for evaluating distant metastasis and staging revealed 18F-FDG uptake in the third lumbar vertebra and other vertebrae. Magnetic resonance imaging could not differentiate bone metastases from benign bone lesions. We considered the possibility of bone marrow reconversion. 111Indium chloride (111In-Cl3) scintigraphy with single-photon emission computed tomography/computed tomography (SPECT/CT) revealed erythroid bone marrow components in the bone lesions. The diagnosis of bone marrow reconversion was pathologically confirmed by a bone biopsy of the third lumbar vertebra. The patient underwent esophagectomy and has remained disease-free in the 2 years since. To the best of our knowledge, this is the first report to describe the usefulness of 111In-Cl3 with SPECT/CT for the diagnosis of bone marrow reconversion.
Keywords 111Indium chloride scintigraphy SPECT/CT bone marrow reconversion 18F-FDG PET/CT bone metastasis
Amo Type Case Report
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 285
End Page 289
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549674
Web of Science KeyUT 000384748600009
JaLCDOI 10.18926/AMO/51909
FullText URL fulltext.pdf
Author Mimura, Hidefumi| Kanazawa, Susumu| Yasui, Kotaro| Fujiwara, Hiroyasu| Hyodo, Tsuyoshi| Mukai, Takashi| Dendo, Shuichi| Iguchi, Toshihiro| Hiraki, Takao| Koshima, Isao| Hiraki, Yoshio|
Abstract <p>This retrospective study evaluated the safety and efficacy of using polidocanol with X-ray fluoroscopy for percutaneous sclerotherapy of venous malformations of the limbs, head, and neck. The subjects were 16 of 18 patients who presented to our department with venous malformations. Two patients were excluded because they were unlikely to benefit from the treatment. Of the 16 included in the study, 1 could not be treated because of inaccessibility, and another was lost to follow-up. Among the 14 cases that we were able to follow-up, 11 cases had had pain as their primary symptom. Following treatment, this symptom remained unchanged in 1 patient, was improved in 4, and had disappeared in 6; however, there was a recurrence of pain for 3 of these patients. Two patients had sought treatment for cosmetic purposes; following treatment, the lesion disappeared in one and showed a significant reduction in the other. The remaining patient presented with a primary symptom of mouth bleeding, which disappeared following treatment. There were no critical complications. Percutaneous sclerotherapy of venous malformations using polidocanol is safe and effective, and permits repeat treatments. The efficacy is especially good for resolving pain, and complications are minor. It is desirable to use fluoroscopy for these procedures</p>
Keywords venous malformation sclerotherapy polidocanol fluoroscopy guidance
Amo Type Article
Published Date 2003-10
Publication Title Acta Medica Okayama
Volume volume57
Issue issue5
Publisher Okayama University Medical School
Start Page 227
End Page 234
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 14679400
Web of Science KeyUT 000186186000003
JaLCDOI 10.18926/AMO/47010
FullText URL 65_5_287.pdf
Author Hiraki, Takao| Gobara, Hideo| Mimura, Hidefumi| Toyooka, Shinichi| Fujiwara, Hiroyasu| Yasui, Kotaro| Sano, Yoshifumi| Iguchi, Toshihiro| Sakurai, Jun| Tajiri, Nobuhisa| Mukai, Takashi| Matsui, Yusuke| Kanazawa, Susumu|
Abstract The application of radiofrequency ablation for the treatment of lung cancer by our group at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences began in June 2001, and in the present report, we review our 10-year experience with this treatment modality at Okayama University Hospital. The local efficacy of radiofrequency ablation for the treatment of lung cancer depends on tumor size and the type of electrode used, but not on tumor type. An important factor for the prevention of local failure may be the acquisition of an adequate ablative margin. The combination of embolization and radiation therapy enhances the local efficacy. Local failure may be salvaged by repeating the radiofrequency ablation, particularly in small tumors. Survival rates after radiofrequency ablation are quite promising for patients with clinical stage I non-small cell lung cancer and pulmonary metastasis from colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. The complications caused by radiofrequency ablation can be treated conservatively in the majority of cases. However, attention should be paid to rare but serious complications. This review shows that radiofrequency ablation is a promising treatment for patients with lung cancer.
Keywords radiofrequency ablation lung cancer local efficacy survival complication
Amo Type Review
Published Date 2011-10
Publication Title Acta Medica Okayama
Volume volume65
Issue issue5
Publisher Okayama University Medical School
Start Page 287
End Page 297
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2011 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22037265
Web of Science KeyUT 000296116400002
JaLCDOI 10.18926/AMO/43830
FullText URL 65_1_49.pdf
Author Iguchi, Toshihiro| Idani, Hitoshi| Asami, Shinya| Endo, Hisashi| Inaba, Yoshitaka| Arai, Yasuaki| Kanazawa, Susumu|
Abstract We administered hepatic arterial infusion chemotherapy (HAIC) prior to FOLFOX to three patients with unresectable liver metastases from colorectal cancer. The patients' disease state was found to be highly advanced based on both computed tomography findings and liver function tests. The treatment strategy included an initial administration of HAIC to control liver metastases and improve liver function in order to facilitate the subsequent safe administration of FOLFOX without drug loss. As the HAIC regimen, 1,000mg/m2 of 5-FU was administered weekly by continuous 5-h infusion after performing laboratory investigations through an implanted port-catheter system. After 3 HAIC cycles administered over 3 consecutive weeks, the mean alkaline phosphatase levels decreased from 969.3IU/l to 422IU/l due to shrinkage of the liver metastases. Thereafter, FOLFOX without drug loss could be safely initiated for all patients. Two patients succumbed 488 and 333 days after HAIC was initiated;the third patient is still alive and has been followed-up for 1215 days. The combined use of HAIC and standard systemic chemotherapy could be a feasible and efficacious treatment in highly advanced cases of liver dysfunction.
Keywords colorectal cancer hepatic arterial infusion chemotherapy liver metastasis port-catheter system
Amo Type Case Report
Published Date 2011-02
Publication Title Acta Medica Okayama
Volume volume65
Issue issue1
Publisher Okayama University Medical School
Start Page 49
End Page 53
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2011 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 21339796
Web of Science KeyUT 000287620500007
JaLCDOI 10.18926/AMO/32906
FullText URL fulltext.pdf
Author Mukai, Takashi| Mimura, Hidefumi| Gobara, Hideo| Takemoto, Mitsuhiro| Himei, Kengo| Hiraki, Takao| Hase, Soichiro| Fujiwara, Hiroyasu| Iguchi, Toshihiro| Tajiri, Nobuhisa| Sakurai, Jun| Yasui, Kotaro| Sano, Yoshifumi| Date, Hiroshi| Kanazawa, Susumu|
Abstract We report the clinical experience of radiofrequency ablation followed by radiation therapy for large primary lung tumors. Two patients with large primary lung tumors were treated with combined radiofrequency ablation and radiation therapy, and good local control was observed. Combined radiofrequency ablation and radiation therapy that involves minimally invasive techniques appears to be promising for the treatment of large lung tumors.
Keywords radiofrequency ablation lung cancer radiation therapy
Amo Type Case Report
Published Date 2007-06
Publication Title Acta Medica Okayama
Volume volume61
Issue issue3
Publisher Okayama University Medical School
Start Page 177
End Page 180
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 17593954
Web of Science KeyUT 000247574700008
JaLCDOI 10.18926/AMO/30731
FullText URL fulltext.pdf
Author Mukai, Takashi| Sato, Shuhei| Iguchi, Toshihiro| Mimura, Hidefumi| Yasui, Kotaro| Gobara, Hideo| Saika, Takashi| Nasu, Yasutomo| Kumon, Hiromi| Kanazawa, Susumu|
Abstract We quantitatively evaluated total and individual renal function by technetium-99m mercaptoacetyltriglycine (Tc-99m MAG3) renal scintigraphy before and after radiofrequency ablation (RFA) of renal tumors. Eleven patients who underwent Tc-99m MAG3 renal scintigraphy 1 week before and after RFA were evaluated (7 men and 4 women ; age range : 23-83 years ; mean age : 60.6 years). Five patients had solitary kidneys, and five had normally or minimally functioning contralateral kidneys. One patient had a renal cell carcinoma in the contralateral kidney. One patient with a solitary kidney underwent RFA a second time for a residual tumor. In patients with a solitary kidney, MAG3 clearance decreased after 5 of 6 RFAs, and in patients with a normally functioning contralateral kidney, MAG3 clearance decreased after 4 of 5 RFAs, but no significant differences were observed between before and after treatments. In addition to the total MAG3 clearance, the split MAG3 clearance was evaluated in patients with a normally functioning contralateral kidney. MAG3 clearance decreased in 4 of 5 treated kidneys, while it adversely increased in the contralateral kidneys after 4 of 5 RFAs. No significant differences, however, were observed between before and after treatments. The results of our study revealed no significant differences in sCr, BUN, CCr, or MAG3 clearance between pre- and post-RFA values. These results support data regarding the functional impact and safety of renal RFA in published reports. We evaluated total and individual renal function quantitatively using Tc-99m MAG3 renal scintigraphy before and after treatment. This scintigraphy was very useful in assessing the effects of RFA on renal function.
Keywords kidney renal tumor radiofrequency ablation Tc-99m MAG3 renal scintigraphy individual renal function
Amo Type Article
Published Date 2006-04
Publication Title Acta Medica Okayama
Volume volume60
Issue issue2
Publisher Okayama University Medical School
Start Page 85
End Page 91
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
Web of Science KeyUT 000237001900003